U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
Bristol-Myers Squibb Company (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. (Source: World Pharma News)
Source: World Pharma News - January 17, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

B cells linked to effective cancer immunotherapy
Cancer patients responded better to immunotherapy and had a better prognosis if their melanoma tumours contained specific clusters of B cells, according to new research from Lund University in Sweden. The study is published in Nature. (Source: World Pharma News)
Source: World Pharma News - January 16, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Edible 'security tag' to protect drugs from counterfeit
Manufacturing prescription drugs with distinct markings, colors, shapes or packaging isn't enough to protect them from counterfeiting, U.S. Drug Enforcement Administration reports have shown. Purdue University researchers are aiming to stump counterfeiters with an edible "security tag" embedded into medicine. (Source: World Pharma News)
Source: World Pharma News - January 16, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted Priority Review in the US for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to 1st-line platinum-based chemotherapy with bevacizumab. (Source: World Pharma News)
Source: World Pharma News - January 15, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Women's blood vessels age faster than men's
New research from the Smidt Heart Institute at Cedars-Sinai showed for the first time that women's blood vessels - including both large and small arteries - age at a faster rate than men's. The findings, published Wednesday in the journal JAMA Cardiology, could help to explain why women tend to develop different types of cardiovascular disease and with different timing than men. (Source: World Pharma News)
Source: World Pharma News - January 15, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Roche and Illumina partner to broaden patient access to genomic testing
Roche (SIX: RO, ROG; OTCQX: RHHBY) has entered into a 15-year, non-exclusive partnership with Illumina to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology. As the understanding of the genomic drivers of cancer evolves, NGS has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. (Source: World Pharma News)
Source: World Pharma News - January 14, 2020 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Exosomes promote remarkable recovery in stroke
It's been almost a quarter century since the first drug was approved for stroke. But what's even more striking is that only a single drug remains approved today. In a publication appearing this month in the journal Translational Stroke Research, animal scientists, funded by the National Institutes of Health, present (Source: World Pharma News)
Source: World Pharma News - January 14, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Amgen announces global diagnostic collaborations
Amgen (NASDAQ: AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based companion diagnostics (CDx), respectively, for investigational cancer treatment AMG 510. (Source: World Pharma News)
Source: World Pharma News - January 13, 2020 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Vitamin B6, leukemia's deadly addiction
Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division. The research team from Cold Spring Harbor Laboratory (CSHL) and Memorial Sloan Kettering Cancer Center (MSK) suggest they could halt the growth of this cancer by limiting its ability to manipulate the enzyme that pushes B6 to make proteins essential for cell division. (Source: World Pharma News)
Source: World Pharma News - January 13, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST) - a type of tumor that occurs in the gastrointestinal tract, (Source: World Pharma News)
Source: World Pharma News - January 10, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Boehringer Ingelheim partners with Enleofen to develop first-in-class anti-IL-11 therapies for a range of fibrotic diseases
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen's preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim's leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company's extensive range of therapeutic antibodies targeting this pathway. (Source: World Pharma News)
Source: World Pharma News - January 10, 2020 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Plant-derived SVC112 hits cancer stem cells, leaves healthy cells alone
The red, tube-shaped flowers of the firecracker bush (Bouvardia ternifolia), native to Mexico and the American Southwest, attract hummingbirds. The bush also provides the chemical bouvardin, which the lab of University of Colorado Cancer Center and CU Boulder researcher, Tin Tin Su, PhD, and others have shown to slow a cancer's ability to make proteins that tell cancer cells to grow and spread. (Source: World Pharma News)
Source: World Pharma News - January 10, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Nuclear radiologists 'outsmart' prostate cancer with an apparently ineffective drug
When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewhat remote, rather idealistic genius sitting alone in their room or laboratory and somehow discovering the most amazing things without every having contact with the 'normal' world. But science is just as much a part of life as any other activity. (Source: World Pharma News)
Source: World Pharma News - January 9, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery
Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary AI drug discovery platform and drug design know-how with Bayer's data and drug discovery capabilities. (Source: World Pharma News)
Source: World Pharma News - January 9, 2020 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Aspirin appears to curb colorectal cancer recurrence and tumor growth
The benefits of a daily aspirin may extend beyond heart health to colorectal cancer treatment, say City of Hope researchers who have found aspirin appears to reduce tumor growth and inhibit recurrence of the disease. The trick now, researchers say, is to determine the right dosage of aspirin that can be used as a daily prophylactic without triggering dangerous side effects such as stomach and brain bleeds. (Source: World Pharma News)
Source: World Pharma News - January 8, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy, to Catalent Inc. (Source: World Pharma News)
Source: World Pharma News - January 7, 2020 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Researchers develop universal flu vaccine that protects against 6 influenza viruses in mice
A novel nanoparticle vaccine that combines two major influenza proteins is effective in providing broad, long-lasting protection against influenza virus in mice, showing promise as a universal flu vaccine, according to a study by the Institute for Biomedical Sciences at Georgia State University. (Source: World Pharma News)
Source: World Pharma News - January 7, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction
AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D). (Source: World Pharma News)
Source: World Pharma News - January 6, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Amgen commences strategic collaboration with BeiGene to expand oncology presence in China
Amgen (NASDAQ: AMGN) announced the successful closing of the transaction to enter into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest pharmaceutical market. (Source: World Pharma News)
Source: World Pharma News - January 6, 2020 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Lilly opens Phase 3 clinical trial in RET-mutant medullary thyroid cancer
Eli Lilly and Company (NYSE: LLY) announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naive RET-mutant medullary thyroid cancer (MTC) patients. This is the second Phase 3 trial to open for selpercatinib, a highly selective and potent, oral investigational new medicine in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. (Source: World Pharma News)
Source: World Pharma News - January 3, 2020 Category: Pharmaceuticals Tags: Featured Eli Lilly and Company Business and Industry Source Type: news

Scientists find a new use for already known anti-cancer drugs
The world scientific community is waging a difficult and prolonged war on cancer. New research in the field of immunogenic cell death can extend the area of drugs application and ensure patients' protection from relapse after therapy. (Source: World Pharma News)
Source: World Pharma News - January 3, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Researchers determine how a specific protein regulates tumor growth
Immune checkpoints are surface proteins that cancer cells use to evade immune response. These surface proteins are critical for cancer cell growth and drugs targeting these proteins have revolutionized the management of patients with a wide array of cancers. Finding a mechanism to degrade these immune checkpoints may allow the immune system to kill cancer cells. (Source: World Pharma News)
Source: World Pharma News - January 2, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves new treatment for adults with migraine
The U.S. Food and Drug Administration approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Ubrelvy is not indicated for the preventive treatment of migraine. (Source: World Pharma News)
Source: World Pharma News - January 1, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) (Source: World Pharma News)
Source: World Pharma News - December 31, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Pharmacies leave customers hanging when it comes to disposing of antibiotics and opioids
Proper disposal of leftover medication, particularly antibiotics and opioids, can help reduce antibiotic resistance, prevent children from being poisoned and stop the misuse of addiction-forming drugs. But a telephone survey conducted by researchers at UC San Francisco found that fewer than half of California pharmacies provided disposal instructions meeting U.S. Food and Drug Administration guidelines, and (Source: World Pharma News)
Source: World Pharma News - December 30, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Intermittent fasting: live 'fast,' live longer?
For many people, the New Year is a time to adopt new habits as a renewed commitment to personal health. Newly enthusiastic fitness buffs pack into gyms and grocery stores are filled with shoppers eager to try out new diets. But, does scientific evidence support the claims made for these diets? (Source: World Pharma News)
Source: World Pharma News - December 27, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves first generics of Eliquis
The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Apixaban is also indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (Source: World Pharma News)
Source: World Pharma News - December 26, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Theravance Biopharma and Pfizer Inc. enter global license agreement for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor program
Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE: PFE) ("Pfizer") today announced that the companies have entered into a global license agreement for Theravance Biopharma's preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized. (Source: World Pharma News)
Source: World Pharma News - December 23, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Researchers identify immune-suppressing target in glioblastoma
Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with anti-PD-1 checkpoint blockade, elevating a new potential target for treating the almost uniformly lethal brain tumor. (Source: World Pharma News)
Source: World Pharma News - December 23, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
Today, the U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. (Source: World Pharma News)
Source: World Pharma News - December 20, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Amgen and Allergan submit Biologics License Application for ABP 798, biosimilar candidate to Rituxan ® (rituximab)
Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA. (Source: World Pharma News)
Source: World Pharma News - December 19, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

FDA approves new type of therapy to treat advanced urothelial cancer
The U.S. Food and Drug Administration granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells - in this case, the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers. (Source: World Pharma News)
Source: World Pharma News - December 19, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Old drug offers new hope for children with devastating disorder
A drug that once helped obese adults lose weight, but was withdrawn from the market due to heart risks, may be safe and effective for children with a life-threatening seizure disorder called Dravet syndrome, say researchers from UCSF Benioff Children's Hospitals and other major treatment centers. (Source: World Pharma News)
Source: World Pharma News - December 18, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
AstraZeneca and MSD Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 5 to recommend Lynparza (olaparib) as a 1st-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer), whose disease has not progressed following 1st-line platinum-based chemotherapy. (Source: World Pharma News)
Source: World Pharma News - December 18, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Filtered coffee helps prevent type 2 diabetes, show biomarkers in blood samples
Coffee can help reduce the risk of developing type 2 diabetes - but only filtered coffee, rather than boiled coffee. New research from Chalmers University of Technology and Umeå University, both in Sweden, show that the choice of preparation method influences the health effects of coffee. (Source: World Pharma News)
Source: World Pharma News - December 17, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. (Source: World Pharma News)
Source: World Pharma News - December 17, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Free tool simplifies cancer research
Every cell contains a vast number of proteins, each of which has a specific function, for example as a receptor for another molecule or an enzyme that catalyses chemical reactions. Disorders of such mechanisms can seriously affect a cell and cause diseases such as cancer, in which the sick cell functions in a fundamentally different way to a healthy cell. (Source: World Pharma News)
Source: World Pharma News - December 16, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm). (Source: World Pharma News)
Source: World Pharma News - December 16, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation
The U.S. Food and Drug Administration today granted accelerated approval to Vyondys 53 (golodirsen) injection to treat Duchenne muscular dystrophy (DMD) patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. It is estimated that about 8 percent of patients with DMD have this mutation. (Source: World Pharma News)
Source: World Pharma News - December 13, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

High-tech method for uniquely targeted gene therapy developed
Neuroscientists at Lund University in Sweden have developed a new technology that engineers the shell of a virus to deliver gene therapy to the exact cell type in the body that needs to be treated. The researchers believe that the new technology can be likened to dramatically accelerating evolution from millions of years to weeks. (Source: World Pharma News)
Source: World Pharma News - December 13, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New set-up for IT at Bayer
Bayer is transforming its IT function to further accelerate the digitalization of the company. Leading IT providers will take over standardized services, such as the provision of digital workplaces for employees or the global operation of IT infrastructure. Internally, the IT function will focus on differentiating solutions for Bayer's businesses. (Source: World Pharma News)
Source: World Pharma News - December 12, 2019 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

The new polymer can kill drug-resistant bacteria
Researchers from Singapore-MIT Alliance for Research and Technology (SMART), MIT's research enterprise in Singapore, and Nanyang Technological University (NTU) have designed an antimicrobial polymer that can kill bacteria resistant to commonly used antibiotics, including the superbug Methicillin-resistant Staphylococcus aureus (MRSA). (Source: World Pharma News)
Source: World Pharma News - December 12, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody drug conjugate (ADC) and potential new medicine, in patients with HER2-positive metastatic breast cancer who received two or more prior HER2-targeted regimens. (Source: World Pharma News)
Source: World Pharma News - December 11, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

A vaccine against chronic inflammatory diseases
Chronic inflammatory bowel diseases, such as Crohn's Disease and ulcerative colitis, are linked to abnormalities of the gut microbiota in humans and in animals. Patients generally present reduced bacterial diversity in their intestinal flora along with excessive levels of bacteria that express a protein called flagellin, which favors their mobility. (Source: World Pharma News)
Source: World Pharma News - December 11, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters
Novartis holded an investor event in London to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D pipeline. Vas Narasimhan, CEO of Novartis, said “Novartis had a year of breakthrough innovation in 2019, with five potential blockbuster NME approvals. The near term brings yet another catalyst-rich period with pipeline progress across the portfolio that can sustain long-term growth. (Source: World Pharma News)
Source: World Pharma News - December 10, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Microcapsules for targeted drug delivery to cancer cells
A team of scientists from Peter the Great St.Petersburg Polytechnic University (SPbPU) together with their colleagues developed a method of targeted drug delivery to cancer cells. The discovery is based on the use of mesenchymal stem cells and microcapsules made of polymeric compounds. (Source: World Pharma News)
Source: World Pharma News - December 10, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA launches app for health care professionals
The U.S. Food and Drug Administration announced the global launch of CURE ID, an internet-based repository that will allow the clinical community to report their experiences treating difficult-to-treat infectious diseases with novel uses of existing FDA-approved drugs through a website, a smartphone or other mobile device. (Source: World Pharma News)
Source: World Pharma News - December 9, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Roche and Spark Therapeutics, Inc. announce extension of tender offer
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the "Shares") of Spark for USD 114.50 per Share, net to the seller thereof in cash, without (Source: World Pharma News)
Source: World Pharma News - December 9, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Leukemia, lymphoma squarely in sights of new class of drugs
UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine reported the findings Dec. 2. (Source: World Pharma News)
Source: World Pharma News - December 6, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

First investigational drug therapy for liver disease NASH awaiting FDA approval
Patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease and a leading cause for liver transplantation in the U.S., currently lack an approved drug therapy, but this may soon change. A large Phase III clinical trial designed in collaboration with Virginia Commonwealth University is the first to demonstrate the safety and effectiveness of an oral medication to treat the disease. (Source: World Pharma News)
Source: World Pharma News - December 5, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news